ASLAN Pharmaceuticals welcomes Dr. Neil Graham to its Board as Independent Director

– SINGAPORE, Singapore –  ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr. Neil Graham, MBBS, MD, MPH to its Board as an independent director.

“We are delighted to welcome Dr Graham to ASLAN’s board of directors. His global expertise in immunology and inflammation, and strategic guidance will be of great value to our team as we approach important milestones in the clinical development of ASLAN004 and ASLAN003 this year.” said Board Chairman, Andrew Howden.

Jun Wu, representative of Alnair Investment, after serving for eight years, has resigned from the board with effect from February 18, 2021, as the fund is reaching the end of its investment cycle.

Kelvin Sun, independent director based in Taiwan, will also be stepping down with effect from February 18, 2021, following the delisting from the Taipei Exchange and shift to the Nasdaq Global Market as the company’s sole listing.

Andrew Howden added, “On behalf of the board, I would like to extend our appreciation to Jun Wu and Kelvin Sun for their support and guidance to the management team during ASLAN’s growth.”

About Dr. Neil Graham

Dr Graham, an expert in immunology and inflammation, has more than 30 years’ experience in global drug development and commercialization, traversing early and late-stage clinical trials in dermatology, allergy, rheumatology, virology, and pulmonology. Dr. Graham is currently Chief Medical Officer of Tiziana Life Sciences plc (Nasdaq: TLSA | LON: TILS) and a director of Pharmaxis Ltd.

Dr. Graham was previously the VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., from 2010 to 2020, where he was appointed Global Strategic Program leader for the dupilumab development program from phase 1 through to its commercial launch. Dr. Graham also led the product development for KEVZARA, an IL-6R antibody for rheumatoid arthritis, and REGN3500, an anti-IL33 antibody for asthma and COPD.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialization, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease.

For more information: http://aslanpharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team